Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 7, Pages 995-1007Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2012.690032
Keywords
caspase-1; inflammasome; inflammation; interleukin-1; P2X7 receptor
Categories
Funding
- Instituto Salud Carlos III
- Fundacion Seneca
Ask authors/readers for more resources
Introduction: The inflammasomes have emerged as key mediators of inflammation and immunity, yet clinical application of this knowledge has been limited by a lack of specific and drug-like antagonists. Recent studies using inflammasome knockout mice have shown that different inflammasomes control immunity in different pathologies. Drug-like antagonists acting up-or down-stream of the inflammasome pathway have been successfully used in clinics as important therapeutics to treat different inflammatory diseases. Areas covered: The current literature has been reviewed on the role of inflammasomes in inflammatory disease, focusing on potential therapeutic applications of selective inflammasome antagonists as anti-inflammatory agents. Particular emphasis has been placed on the potential role of the different inflammasomes in common inflammatory diseases. The latest clinical developments for drugs targeting inflammasome pathways are covered. Expert opinion: Recent studies using inflammasome knockout mice suggest its importance as a potential therapeutic target for the treatment of inflammatory disease. However, efficacious antagonists for the inflammasome for use in clinical studies are still at an early stage of development. Developing selective inflammasome antagonists is a challenge that if met, offers promise for the treatment of chronic inflammatory diseases. Major developments in this area will include the identification of reliable high-throughput screening methods for compounds directly targeting inflammasome assembly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available